Dr. Mauro Discusses Drug Adherence Among CML Patients

Video

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don't adhere to their medication.

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don’t adhere to their medication.

Mauro says once the disease has been treated, there are minimal symptoms. However, the therapies used to treat CML can lead to chronic low-grade adverse events. Since CML treatment is indefinite, this can be challenging for patients to deal with, Mauro says.​

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Image of a woman with wavy brown hair in front of a blue background
Photo of a man wearing a suit with a bowtie in front of an Oncology Nursing News backdrop
Photo of a woman with blond hair wearing a white and black blazer